{"filing":{"accession_number":"0001654954-26-006251","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"a1370k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426006251/a1370k.htm"},"events":[{"id":14428,"run_id":12846,"accession_number":"0001654954-26-006251","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This disclosure announces European Commission approval of Enhertu (trastuzumab deruxtecan) as the first tumor-agnostic HER2-directed therapy for previously treated HER2-positive solid tumors. The approval is a significant regulatory milestone for a key oncology asset, supported by Phase II trial data across multiple tumor types (DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02). The filing also notes a $25 million milestone payment due to Daiichi Sankyo. While this is a regulatory approval event rather than a discrete financial transaction or executive action, it represents a material operational and commercial milestone that would affect investor assessment of the company's oncology portfolio and revenue prospects.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":11858,"accession_number":"0001654954-26-006251","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces European Commission approval of Enhertu (trastuzumab deruxtecan) as the first tumor-agnostic HER2-directed therapy for previously treated HER2-positive solid tumors. The approval is a significant regulatory milestone for a key oncology asset, supported by Phase II trial data across multiple tumor types (DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02). The filing also notes a $25 million milestone payment due to Daiichi Sankyo. While this is a regulatory approval event rather than a discrete financial transaction or executive action, it represents a material operational and commercial milestone that would affect investor assessment of the company's oncology portfolio and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:45:41.634844+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-06-29"}]}